Allergic reaction to the liposomal component of liposomal amphotericin B

被引:0
|
作者
S. Cesaro
Elisabetta Calore
Chiara Messina
Luigi Zanesco
机构
[1] II Clinic of Paediatrics,
[2] Paediatric Oncology-Haematology Division,undefined
[3] Department of Paediatrics,undefined
[4] University of Padua,undefined
[5] Via Giustiniani 3,undefined
[6] I-35128 Padua,undefined
[7] Italy e-mail: seguno@child.pedi.unipd.it,undefined
[8] Tel.: +39-049-8213579,undefined
[9] Fax: +39-049-8213510,undefined
来源
关键词
Key words Ambisome; Amphotericin B; Adverse effects; Liposomes; Fungal infection;
D O I
暂无
中图分类号
学科分类号
摘要
 A case of severe allergic reaction arising during treatment with Ambisome and unresponsive to antihistamine and steroid medication is reported. A 2.9-year-old female child with Hurler's syndrome received an allogeneic cord blood transplant from an unrelated donor. During the aplastic phase, liposomal amphotericin B (Ambisome) was administered as part of an empirical treatment for persistent fever. The patient developed an extensive maculopapular rash and severe itching that resolved only on discontinuation of the drug. The patient subsequently had interstitial pneumonia with ingravescent respiratory failure in spite of adequate antibiotic and antiviral treatment. Treatment with conventional amphotericin B was considered essential in this critically ill patient, and the conventional formulation was administered for 20 days without causing any reaction. Severe allergic reaction to Ambisome is a rare event but, taking into account that premedication or dose testing is not recommended for this formulation, careful monitoring of the patient being treated for the first time is warranted.
引用
收藏
页码:284 / 286
页数:2
相关论文
共 50 条
  • [21] The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome®)
    Jensen, Gerard M.
    JOURNAL OF LIPOSOME RESEARCH, 2017, 27 (03) : 173 - 179
  • [22] Liposomal amphotericin B-the past
    Bruggemann, R. J.
    Jensen, G. M.
    Lass-Florl, C.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 : 3 - 10
  • [23] Disposition of aerosolized liposomal amphotericin B
    Lambros, MP
    Bourne, DWA
    Abbas, SA
    Johnson, DL
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (09) : 1066 - 1069
  • [24] Liposomal amphotericin B-the present
    Maertens, J.
    Pagano, L.
    Azoulay, E.
    Warris, A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 : 11 - 20
  • [25] Clinical safety of liposomal amphotericin B
    Suberviola, Borja
    REVISTA IBEROAMERICANA DE MICOLOGIA, 2021, 38 (02): : 56 - 60
  • [26] Analysis of the use of liposomal amphotericin B
    Gonzalez Martinez, Maria
    Marino Martinez, Carolina
    Baldominos Utrilla, Gema
    Fernandez Martinez, Maria Nelida
    REVISTA IBEROAMERICANA DE MICOLOGIA, 2014, 31 (02): : 109 - 113
  • [27] Regulated bioanalysis of liposomal amphotericin B to support pharmacokinetic studies of liposomal drugs
    Zhang, Xueyuan
    Ji, Yuhuan
    Liu, Jinzhi
    Liu, Ji
    Li, Chunlei
    Wang, Laixin
    Meng, Min
    Zhao, Limei
    BIOANALYSIS, 2022, 14 (07) : 421 - 439
  • [28] Is liposomal amphotericin B really safety in neonates?
    Karadag-Oncel, Eda
    Ozsurekci, Yasemin
    Yurdakok, Murat
    Kara, Ates
    EARLY HUMAN DEVELOPMENT, 2013, 89 (01) : 35 - 36
  • [29] Liposomal amphotericin B indicated for empirical therapy
    不详
    AIDS PATIENT CARE AND STDS, 1997, 11 (06) : 458 - 459
  • [30] Liposomal Amphotericin B and Leishmaniasis: Dose and Response
    Sundar, Shyam
    Chakravarty, Jaya
    JOURNAL OF GLOBAL INFECTIOUS DISEASES, 2010, 2 (02) : 159 - 166